620593-93-3

Basic information

• Product Name: 4-hydroxy-2-(2-hydroxyethyl)-2-(3-methoxyphenyl)butanenitrile
• Synonyms: 4-hydroxy-2-(2-hydroxyethyl)-2-(3-methoxyphenyl)butanenitrile
• CAS NO: 620593-93-3
• Molecular Weight: 235.283
• Mol File: 620593-93-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-hydroxy-2-(2-hydroxyethyl)-2-(3-methoxyphenyl)butanenitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydroxy-2-(2-hydroxyethyl)-2-(3-methoxyphenyl)butanenitrile(620593-93-3)
• EPA Substance Registry System: 4-hydroxy-2-(2-hydroxyethyl)-2-(3-methoxyphenyl)butanenitrile(620593-93-3)

Safety Data

• Hazardous Substances Data: 620593-93-3(Hazardous Substances Data)

Upstream product

• 19924-43-7 3-methoxyphenylacetonitrile 

Downstream Products

• 1143579-07-0 C₁₆H₂₂N₂O 
• 1143579-10-5 C₂₃H₂₈N₂O₂ 
• 1143579-11-6 4-(3-methoxyphenyl)-1-[2-(trifluoromethoxy)phenyl]piperidine-4-carbonitrile 
• 1143579-08-1 1,4-bis(3-methoxyphenyl)piperidine-4-carbonitrile 
• 850884-16-1 1-(2-methoxyphenyl)-4-(3-methoxyphenyl)piperidine-4-carbonitrile 
• 1143579-09-2 4-(3-methoxyphenyl)-1-(4-methoxyphenyl)piperidine-4-carbonitrile 
• 106896-79-1 4-(3-methoxyphenyl)-1-phenylpiperidine-4-carbonitrile 
• 5460-79-7 1-methyl-4-(m-methoxyphenyl)-4-cyanopiperidine 
• 620593-95-5 4-(3-methoxyphenyl)-1-(diphenylmethyl)piperidine-4-carbonitrile 
• 1143579-12-7 4-(3-methoxyphenyl)-1-[2-(2,2,2-trifluoroethoxy)phenyl]piperidine-4-carbonitrile 
• 109254-16-2 1-benzyl-4-(3-methoxy-phenyl)-piperidine-4-carbonitrile 
• 867262-60-0 methyl 4-(3-hydroxyphenyl)-1-(2,2,2-trifluoroethyl)piperidine-4-carboxylate 
• 867262-59-7 methyl 4-(3-methoxyphenyl)-1-(2,2,2-trifluoroethyl)-piperidine-4-carboxylate 
• 850884-29-6 4-(3-methoxyphenyl)-1-pyrimidin-2-ylpiperidine-4-carbonitrile 

Relevant articles and documents

Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: Dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression

A family of 1,4-diarylpiperidine-4-methylureas were designed and synthesized as novel dual effectors on ACAT and LDL receptor expression. We examined SAR of the synthesized compounds focusing on substitution at the three aromatic parts of the starting compound 1 and succeeded in identifying essential substituents for inhibition of ACAT and up-regulation of hepatic LDL receptor expression. Especially, we found that compound 12f, which can easily be prepared, has biological properties comparable to those of SMP-797, a promising ACAT inhibitor. In addition, the in vitro effects of 12f on lipid metabolism were substantially superior to those of a known ACAT inhibitor, Avasimibe.

NOVEL SULFONAMIDE DERIVATIVE

A compound of the formula (1): wherein m, n and p is independently an integer of 0 to 4 with the proviso that 3 a?| m + n a?| 8; X is the formula: NR4, etc.; R1, R3 and R4 are a substituted or unsubstituted aryl group, etc.; R2 is a hydrogen atom, etc.; a, b, c, d, e and f are a hydrogen atom or a substituted or unsubstituted alkyl group, etc.; Y is the formula: -SO2-, etc.; and Z is an oxygen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt of the same has an activity of potentiating an expression of a low density lipoprotein receptor and thus is useful as an agent for treating hyperlipidemia or arteriosclerosis.